Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) is helping to protect against meningitis B in the Saguenay-Lac-Saint-Jean region, which has had the most cases of the disease in ...

GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

The safety profile of MenABCWY was reported to be similar to Bexsero and Menveo. The FDA granted Priority Review to the BLA for CHIKV VLP, an adjuvanted virus-like particle (VLP)-based vaccine ...

developed new mathematical models to predict the number of meningococcal disease cases which could be averted by introducing the vaccine Bexsero. The models developed by the Bristol team were the ...

Other meningococcal strains ... receive the MenACWY vaccine in school years nine and ten. The MenB vaccine, marketed as Bexsero, is produced by GSK while the MenC vaccine component is part ...

Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11–55 years.

“Meningococcal bacteria are all around us in the world ... is spread through contact with saliva from the nose and throat. The newly-developed vaccine, called Bexsero, protects against the B strain of ...

If under the age of 23, a quadrivalent meningococcal conjugate vaccine (MCV4) on or after your 16th birthday. Acceptable versions: Menactra, Menveo, or MCV4. Non-acceptable versions: Bexsero or ...